News
Cigna will cap out-of-pocket costs at $200 per month for patients using the weight-loss drugs Wegovy and Zepbound through an ...
Researchers are beginning to wonder if blockbuster drugs like Wegovy, Ozempic and Zepbound could play a role in preventing ...
Tirzepatide (Zepbound) led to more weight loss than semaglutide (Wegovy) in a clinical trial funded by Eli Lilly. Participants who received tirzepatide also had greater improvements in metabolic risk ...
People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications.
Online weight-loss company Noom has begun offering smaller doses of compounded versions of Novo Nordisk's Wegovy as the U.S.
The suit comes amid recent studies showing a link between vision complications and people taking drugs containing semaglutide ...
The first development that occurred is that it evaluated its drug tirzepatide (Zepbound) against Novo Nordisk (NVO) Wegovy (Semaglutide ... the phase 3 ACHEIVE-1 study using oral GLP-1 receptor ...
People in the study who were using Zepbound lost about 50% more weight those who got Wegovy, making it the superior drug in terms of weight loss. One curious thing about the study was that all the ...
Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down. The move ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results